Low Maternal DLK1 Levels at 26 Weeks Is Associated With Small for Gestational Age at Birth.
DLK1
biomarker
fetal growth restriction
placental vascular dysfunction
small for gestational age (SGA)
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
12
2021
accepted:
26
01
2022
entrez:
17
3
2022
pubmed:
18
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Detecting SGA (small for gestational age) during pregnancy improves the fetal and neonatal prognosis. To date, there is no valid antenatal biomarker of SGA used in clinical practice. Maternal circulating DLK1 (delta-like non-canonical notch ligand 1) levels have been shown to be significantly lower in pregnant women at 36 weeks of gestation (WG) who delivered a SGA newborn than in controls. Data in the literature are contradictory on the association between maternal circulating DLK1 levels and placental vascular dysfunction. The objective was to determine if maternal DLK1 levels in the second trimester of pregnancy are predictive of SGA, and to assess whether the measurement of DLK1 levels in maternal blood could be a means to distinguish SGA with placental vascular dysfunction from that due to other causes. We conducted a nested cased-control study within the EDEN mother-child cohort. 193 SGA (birth weight < 10
Identifiants
pubmed: 35295988
doi: 10.3389/fendo.2022.836731
pmc: PMC8919710
doi:
Substances chimiques
Calcium-Binding Proteins
0
DLK1 protein, human
0
Membrane Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
836731Informations de copyright
Copyright © 2022 Pham, Mitanchez, Forhan, Perin, Le Bouc, Brioude, Sobrier, Heude and Netchine.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Obstet Gynecol. 2018 Feb;218(2S):S790-S802.e1
pubmed: 29422212
Diabet Med. 2003 May;20(5):339-48
pubmed: 12752481
BJOG. 2021 Jan;128(1):77-85
pubmed: 32588532
Semin Perinatol. 2004 Feb;28(1):33-40
pubmed: 15058900
BMJ. 2013 Jan 24;346:f108
pubmed: 23349424
BJOG. 2015 Mar;122(4):518-27
pubmed: 25346493
Ultrasound Obstet Gynecol. 2020 Aug;56(2):298-312
pubmed: 32738107
Front Endocrinol (Lausanne). 2013 Jul 03;4:79
pubmed: 23840193
Epigenetics. 2015;10(9):842-9
pubmed: 26186239
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2112-2120
pubmed: 30462238
Am J Obstet Gynecol. 2018 Feb;218(2S):S725-S737
pubmed: 29275822
Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:52-56
pubmed: 29408751
J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):921-8
pubmed: 24210709
Diabetes Care. 2012 Apr;35(4):848-9
pubmed: 22338099
Semin Perinatol. 2008 Aug;32(4):274-80
pubmed: 18652928
Lancet. 1989 Sep 9;2(8663):577-80
pubmed: 2570282
Differentiation. 2000 Aug;66(1):49-59
pubmed: 10997592
J Med Genet. 1991 Aug;28(8):511-4
pubmed: 1681108
Nat Genet. 2016 Dec;48(12):1473-1480
pubmed: 27776119
Pediatr Dev Pathol. 2016 Jan-Feb;19(1):37-46
pubmed: 26368794
Cytokine Growth Factor Rev. 2019 Apr;46:17-27
pubmed: 30930082
Ultrasound Obstet Gynecol. 2016 Sep;48(3):333-9
pubmed: 26909664
J Pediatr. 2012 Apr;160(4):578-583.e2
pubmed: 22048041
Acta Paediatr. 2017 Aug;106(8):1230-1238
pubmed: 28382722
Placenta. 2020 Feb;91:24-30
pubmed: 32174303
Cytokine. 2015 Oct;75(2):338-43
pubmed: 26242929
Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):523-534
pubmed: 30086872
Placenta. 2013 Apr;34(4):331-4
pubmed: 23410724
Pediatrics. 2003 Jun;111(6 Pt 1):1253-61
pubmed: 12777538
J Clin Endocrinol Metab. 2007 Mar;92(3):804-10
pubmed: 17200164
Mol Cell Biol. 2002 Aug;22(15):5585-92
pubmed: 12101250
Int J Epidemiol. 2016 Apr;45(2):353-63
pubmed: 26283636